Cell type-specific transactivation of the VCAM-1 promoter through an NF-kappa B enhancer motif.

The Journal of Biological Chemistry
M AhmadR M Medford

Abstract

Cytokine activation of vascular cell adhesion molecule-1 (VCAM-1) gene expression by endothelial cells is an important feature in a variety of vascular inflammatory responses. Cytokines transcriptionally activate the VCAM-1 promoter in endothelial cells at least in part through two closely linked NF-kappa B enhancer motifs, kappa L-kappa R (positions -77 and -63). However, cytokine activation of the dimeric NF-kappa B transcriptional factor (p50+p65 subunits) occurs in almost all cell types, whereas VCAM-1 gene expression exhibits a cell type-specific pattern of expression. Tumor necrosis factor-alpha markedly transactivated a transiently transfected minimal kappa L-kappa R motif-driven VCAM-1 promoter, p85VCAMCAT, in passaged human vascular endothelial cells but not in the human epithelial cell line, HeLa suggesting that cell type-specific factors may function through the kappa L-kappa R motif. Both cell types exhibited similar inductions of NF-kappa DNA binding activity and transcriptional activity. However, co-transfection of HeLa cells with p65 and p50 expression vectors demonstrated that the minimal VCAM-1 promoter was effectively transactivated by p65 alone but that additional co-expression of p50 blocked this activity. F...Continue Reading

References

Dec 1, 1992·The Journal of Experimental Medicine·A S NeishT Collins
Mar 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·D W BallardW C Greene
May 1, 1992·Genes & Development·M KretzschmarR G Roeder
Aug 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·K F MontgomeryJ M Harlan
Jun 1, 1991·Journal of Virology·P M Richardson, T D Gilmore
May 1, 1990·Molecular and Cellular Biology·T A Libermann, D Baltimore
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·L OsbornG J Nabel
Jan 18, 1994·Proceedings of the National Academy of Sciences of the United States of America·A Ray, K E Prefontaine
Oct 1, 1993·Molecular and Cellular Biology·C Kunsch, C A Rosen
Jan 1, 1993·International Review of Cytology·M GrilliM J Lenardo

❮ Previous
Next ❯

Citations

Mar 6, 1997·The American Journal of Cardiology·A P SelwynP Ganz
Oct 10, 2002·Biochemical and Biophysical Research Communications·Byung-Heon LeeIn-San Kim
Dec 20, 1996·Atherosclerosis·J H LinM B Stemerman
Aug 15, 1998·Annals of the New York Academy of Sciences·A MantovaniM Introna
Jan 1, 1996·Annual Review of Immunology·A S Baldwin
Feb 12, 2014·The Journal of Experimental Medicine·Chen WangJordan S Pober
Mar 1, 1997·Arteriosclerosis, Thrombosis, and Vascular Biology·M Introna, A Mantovani
Oct 11, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Takashi MinamiWilliam C Aird
Jan 14, 1999·The American Journal of Physiology·T J KalogerisJ S Alexander
Oct 1, 2003·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Robert A BucekMehrdad Baghestanian
Aug 6, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Rebecca A ShillingAnne I Sperling
Jun 18, 1997·Biochemical and Biophysical Research Communications·J XuC Y Hsu

❮ Previous
Next ❯

Related Concepts

Related Feeds

ASBMB Publications

The American Society for Biochemistry and Molecular Biology (ASBMB) includes the Journal of Biological Chemistry, Molecular & Cellular Proteomics, and the Journal of Lipid Research. Discover the latest research from ASBMB here.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.